GlassScriptPhysician profile
Duc Q Vu
NPI 1770573172
$354.91
in general payments reported to CMS, 2019-2025
12 companies · $1.66 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.74 · 2022: $24.62 · 2023: $110 · 2024: $133 · 2025: $1.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209 · Education: $35.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.11 |
| Education | $35.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $85.74 | 2019 | |
| Horizon Therapeutics Plc | $45.67 | 2023 | Krystexxa |
| Amgen INC. | $45.59 | 2024 | Tavneos |
| Travere Therapeutics, INC. | $35.44 | 2024-2025 | Filspari |
| Mozarc Medical US LLC | $29.68 | 2023 | Chameleon |
| Daiichi Sankyo INC. | $24.62 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.18 | 2024 | Givlaari |
| Glaxosmithkline, LLC. | $18.41 | 2023 | Jesduvroq |
| Nxstage Medical, INC. | $15.78 | 2023 | Nxstage System One, Liberty Select Cycler |
| Novartis Pharmaceuticals Corporation | $15.72 | 2024 | |
| Lilly USA, LLC | $14.08 | 2024 | Jardiance |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.